Variable
Mean ± SD |
Older recipients (n=33) |
Younger recipients (n=33) |
P-value |
| Age (years) |
73.6 ± 2.7 |
55.3 ±11.4 |
<0.001 |
| Males |
16 (48%) |
11 (33%) |
NS |
| African American |
8 (24%) |
13 (39%) |
NS |
| Recipient BMI (kg/m2) |
26.5 ± 4.7 |
26.6 ± 5.3 |
NS |
| Duration of dialysis (months) |
29.2 ± 22.5 |
29.0 ± 26.6 |
NS |
| Time on waiting list (months) |
15 ± 11 |
16 ± 16.5 |
NS |
Renal replacement therapy pretransplant
-Hemodialysis
-Peritoneal dialysis |
24 (73%)
4 (12%) |
24 (73%)
6 (18%) |
NS
NS
|
| Preemptive transplant |
5 (15%) |
3 (9%) |
NS |
| Retransplant |
1 (3%) |
1 (3%) |
NS |
Number of HLA mismatches
- 0
- 1-3
- 4-6 |
0
9
24 |
0
2
31 |
0.04 |
Cause of end stage renal disease
Diabetes
Hypertension
Other |
14 (42%)
9 (27%)
10 (30%) |
10 (30%)
3 (9%)
20 (61%) |
NS |
Panel reactive antibody levels
- 0-10%
- 11-49%
- 50-100% |
22
5
6 |
31
1
1 |
0.01 |
| Cold ischemia (hours) |
24.6 ± 8.8 |
25.1 ± 7.1 |
NS |
Induction immunosuppression
-Alemtuzumab
-Rabbit antithymocyte globulin
-Basiliximab |
25
8
0 |
25
7
1 |
NS |
Maintenance Immunosuppression
- Tacrolimus + MycophenolateMofetil
- Tacrolimus + MycophenolateMofetil + Prednisone
- Cyclosporine + MycophenolateMofetil
- Cyclosporine + MycophenolateMofetil + Prednisone |
12
17
0
4 |
12
18
2
1 |
NS |
